Download PDF
Exp Clin Endocrinol Diabetes 2006; 114(2): 75-81
DOI: 10.1055/s-2006-923885
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Cardiovascular Risk Management by Blocking the Endocannabinoid System

P. Bramlage1 , I. Mühlen2 , H. Randeva3 , D. Spanswick3 , H. Lehnert2 , 3
  • 1Institute for Clinical Pharmacology, Technical University, Dresden, Germany
  • 2Department of Endocrinology and Metabolism, University of Magdeburg, Magdeburg, Germany
  • 3Warwick University, Medical School, Coventry, UK
Further Information

Publication History

Received: May 31, 2005 First decision: August 25, 2005

Accepted: November 14, 2005

Publication Date:
29 March 2006 (online)

Also available at
    Permissions and Reprints

Abstract

The specific blockade of endocannabinoids at the level of the cannabinoid receptor 1 (CB1 receptor) is a new therapeutic option to reduce body weight and manage cardiovascular risk. Although clinical trials are underway to document the safety and efficacy of this approach, much is still unknown about this endogenous system. Endocannabinoids and their receptors are expressed in the central nervous system as well as in the periphery and regulate the central neural circuits for food uptake and peripheral metabolic circuits. Within the context of food uptake, the stimulation of the CB1 receptor with Δ9-tetrahydrocannabiol (Δ9-THC) enhances food consumption, while its blockade with receptor antagonists is an emerging relevant therapeutic means to reduce body weight. Rimonabant is the first of a new class of drugs that interferes with the endocannabinoid system by blocking the CB1 receptor. In recent clinical studies, a substantial reduction in body weight and waist circumference was associated with an improvement of the cardiovascular risk profile. In particular, increased HDL cholesterol, decreased serum triglycerides and improved insulin sensivity were observed. Further research will serve to establish the role of these compounds in cardiovascular risk management.

Key words

Overweight - rimonabant - endocannabinoid system - cardiovascular risk - metabolic syndrome

References

  • 1 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.  Circulation. 2002;  106 3143-3421
    PubMedGoogle Scholar
  • 2 Arnone M, Maruani J. et al . Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors.  Psychopharmacology (Berl). 1997;  132 104-106
    CrossrefPubMedGoogle Scholar
  • 3 Bensaid M, Gary-Bobo M. et al . The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.  Mol Pharmacol. 2003;  63 908-914
    CrossrefPubMedGoogle Scholar
  • 4 Bergmann K, Mensink G. Anthropometric data and obesity.  Gesundheitswesen. 1999;  61 Spec No 2 S115-S120
    PubMedGoogle Scholar
  • 5 Bramlage P, Wittchen H U. et al . Recognition and management of overweight and obesity in primary care in Germany.  Int J Obes Relat Metab Disord. 2004;  28 1299-1308
    CrossrefPubMedGoogle Scholar
  • 6 Brown C. A tale of use and abuse. American Chemical Society - 222nd National Meeting (Part XV). Chicago, IL, USA: August 26 - 30. 2001
    Google Scholar
  • 7 Burdyga G, Lal S. et al . Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin.  J Neurosci. 2004;  24 2708-2715
    CrossrefPubMedGoogle Scholar
  • 8 Cani P D, Montoya M L. et al . Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.  Br J Nutr. 2004;  92 757-761
    CrossrefPubMedGoogle Scholar
  • 9 Christopoulos A, Coles P. et al . Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.  Br J Pharmacol. 2001;  132 1281-1291
    CrossrefPubMedGoogle Scholar
  • 10 Cleland J G, Ghosh J. et al . Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HEFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO-Lipids and cardiac resynchronisation therapy in heart failure.  Eur J Heart Fail. 2004;  6 501-508
    PubMedGoogle Scholar
  • 11 Cota D, Marsicano G. et al . Endogenous cannabinoid system as a modulator of food intake.  Int J Obes Relat Metab Disord. 2003;  27 289-301
    CrossrefPubMedGoogle Scholar
  • 12 Cota D, Marsicano G. et al . The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.  J Clin Invest. 2003 b;  112 423-431
    CrossrefPubMedGoogle Scholar
  • 13 Devane W A. Dysarz FA 3rd et al . Determination and characterization of a cannabinoid receptor in rat brain.  Mol Pharmacol. 1988;  34 605-613
    PubMedGoogle Scholar
  • 14 Devane W A, Hanus L. et al . Isolation and structure of a brain constituent that binds to the cannabinoid receptor.  Science. 1992;  258 1946-1949
    CrossrefPubMedGoogle Scholar
  • 15 Di Marzo, Bifulco M. et al . The endocannabinoid system and its therapeutic exploitation.  Nat Rev Drug Discov. 2004;  3 771-784
    CrossrefPubMedGoogle Scholar
  • 16 Di Marzo, Goparaju S K. et al . Leptin-regulated endocannabinoids are involved in maintaining food intake.  Nature. 2001;  410 822-825
    CrossrefPubMedGoogle Scholar
  • 17 Freedland C S, Poston J S. et al . Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding.  Pharmacol Biochem Behav. 2000;  67 265-270
    CrossrefPubMedGoogle Scholar
  • 18 Gomez R, Navarro M. et al . A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.  J Neurosci. 2002;  22 9612-9617
    PubMedGoogle Scholar
  • 19 Guerre-Millo M. Adipose tissue hormones.  J Endocrinol Invest. 2002;  25 855-861
    PubMedGoogle Scholar
  • 20 Hao S, Avraham Y. et al . Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice.  Eur J Pharmacol. 2000;  392 147-156
    CrossrefPubMedGoogle Scholar
  • 21 Harrold J A, Elliott J C. et al . Down-regulation of cannabinoid-1 (CB‐1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food?.  Brain Res. 2002;  952 232-238
    CrossrefPubMedGoogle Scholar
  • 22 Hildebrandt A L, Kelly-Sullivan D M. et al . Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice.  Eur J Pharmacol. 2003;  462 125-132
    CrossrefPubMedGoogle Scholar
  • 23 Hill J O, Wyatt H R. et al . Obesity and the environment: where do we go from here?.  Science. 2003;  299 853-855
    CrossrefPubMedGoogle Scholar
  • 24 Izzo A A. Cannabinoids and intestinal motility: welcome to CB2 receptors.  Br J Pharmacol. 2004;  142 1201-1202
    CrossrefPubMedGoogle Scholar
  • 25 Jamshidi N, Taylor D A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats.  Br J Pharmacol. 2001;  134 1151-1154
    CrossrefPubMedGoogle Scholar
  • 26 Kirkham T C, Williams C M. Endogenous cannabinoids and appetite.  Nutr Res Rev. 2001;  14 65-86
    PubMedGoogle Scholar
  • 27 Kirkham T C, Williams C M. et al . Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol.  Br J Pharmacol. 2002;  136 550-557
    CrossrefPubMedGoogle Scholar
  • 28 Klein T W, Newton C. et al . The cannabinoid system and immune modulation.  J Leukoc Biol. 2003;  74 486-496
    CrossrefPubMedGoogle Scholar
  • 29 Lange J H, Coolen H K. et al . Synthesis, biological properties, and molecular modeling investigations of novel 3, 4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.  J Med Chem. 2004;  47 627-643
    CrossrefPubMedGoogle Scholar
  • 30 Lange J H, Kruse C. et al .4,5-Dihydro-1H-pyrazole derivatives having CB1-antagonistis activity. WO 017700 2001. 2001
    Google Scholar
  • 31 Liu Y L, Connoley I P. et al . Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice.  Int J Obes Relat Metab Disord. 2005;  29 183-187
    CrossrefPubMedGoogle Scholar
  • 32 Matsuda L A, Lolait S J. et al . Structure of a cannabinoid receptor and functional expression of the cloned cDNA.  Nature. 1990;  346 561-564
    CrossrefPubMedGoogle Scholar
  • 33 McAllister S D, Glass M. CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids.  Prostaglandins Leukot Essent Fatty Acids. 2002;  66 161-171
    CrossrefPubMedGoogle Scholar
  • 34 McPartland J M, Glass M. Functional mapping of cannabinoid receptor homologs in mammals, other vertebrates, and invertebrates.  Gene. 2003;  312 297-303
    CrossrefPubMedGoogle Scholar
  • 35 Mechoulam R, Ben-Shabat S. et al . Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.  Biochem Pharmacol. 1995;  50 83-90
    CrossrefPubMedGoogle Scholar
  • 36 Medvedev A, Robidoux J. et al .Molecular Control of adipogenesis and obesity. Keystone, CO, USA: Keystone Symposium. 2002
    Google Scholar
  • 37 Merker N, Wagner N. et al . Early prevention of obesity and cardiovascular diseases.  Dtsch Med Wochenschr. 2002;  127 2661-2663
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Merker N, Wagner N. et al . Frühzeitige Prävention von Adipositas und Herz-Kreislauferkrankungen.  Dtsch Med Wochenschr. 2002 b;  127 2661-2663
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Peeters A, Barendregt J J. et al . Obesity in adulthood and its consequences for life expectancy: a life-table analysis.  Ann Intern Med. 2003;  138 24-32
    PubMedGoogle Scholar
  • 40 Pertwee R G. Pharmacology of cannabinoid CB1 and CB2 receptors.  Pharmacol Ther. 1997;  74 129-180
    PubMedGoogle Scholar
  • 41 Pertwee R G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.  Expert Opin Investig Drugs. 2000;  9 1553-1571
    CrossrefPubMedGoogle Scholar
  • 42 Pi-Sunyer F X, Aronne L J. et al . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients.  JAMA. 2006;  295 761-775
    CrossrefPubMedGoogle Scholar
  • 43 Plasse T F, Gorter R W. et al . Recent clinical experience with dronabinol.  Pharmacol Biochem Behav. 1991;  40 695-700
    CrossrefPubMedGoogle Scholar
  • 44 Ravinet Trillou C, Arnone M. et al . Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.  Am J Physiol Regul Integr Comp Physiol. 2003;  284 R345-R353
    CrossrefPubMedGoogle Scholar
  • 45 Salzet M, Stefano G B. The endocannabinoid system in invertebrates.  Prostaglandins Leukot Essent Fatty Acids. 2002;  66 353-361
    CrossrefPubMedGoogle Scholar
  • 46 Singh R B, Rastogi S S. et al . Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up.  BMJ. 1992;  304 1015-1019
    PubMedGoogle Scholar
  • 47 Van Gaal L F, Rissanen A M. et al . Effects of the endocannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
    CrossrefPubMedGoogle Scholar
  • 48 Williams C M, Kirkham T C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors.  Psychopharmacology (Berl). 1999;  143 315-317
    CrossrefPubMedGoogle Scholar
  • 49 Xie X Q, Pavlopoulos S. et al . Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling.  J Med Chem. 1998;  41 167-174
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Hendrik Lehnert

Klinik für Endokrinologie und Stoffwechselkrankheiten
Medizinische Fakultät der Otto-von-Guericke-Universität

Leipziger Straße 44

39120 Magdeburg

Germany

Phone: + 49 (0)3916715445

Email: Hendrik.Lehnert@medizin.uni-magdeburg.de